Daraxonrasib

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

The move lets eligible patients at 10 community hospitals start daraxonrasib before full approval because a phase 3 trial roughly doubled survival for treated patients.